4D pharma plc (DDDD.L)
| Previous close | 33.10 |
| Open | 32.90 |
| Bid | 33.80 x 0 |
| Ask | 34.35 x 0 |
| Day's range | 32.75 - 35.45 |
| 52-week range | 24.47 - 109.00 |
| Volume | |
| Avg. volume | 3,614,395 |
| Market cap | 62.474M |
| Beta (5Y monthly) | 3.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -44.10 |
| Earnings date | 30 Mar 2022 - 04 Apr 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
4D pharma to Present at the H.C. Wainwright Global Investment Conference
LEEDS, UK,, May 19, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma, will present at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.
- Business Wire
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
LEEDS, England, May 17, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the presentation of a late-breaking poster on data from Part A of the Phase I/II trial of MRx-4DP0004 for the treatment of asthma. The poster is being presented at the 2022 American Thoracic Society (ATS) International Conference, May 13-18, 2022 in San Francisco, CA, US.
- Business Wire
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
LEEDS, England, March 31, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022.
